Travere Therapeutics, Inc.
- TVTX
- NASDAQ
- Biotechnology
- Rare Kidney Disease Drugs
- Sparsentan (FILSPARI)
$49.60
Today −6.04%Quote Oct 16, 2026, 08:00 PM UTC
−23.39%over the last month
Max drawdown −23.4%From 1-month high −23.4%3 months −10.6%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$4.68B
Quote Oct 16
Next earnings
Oct 29
Expected, not confirmed
Analyst target
$76.00
+53.2% from here
Floor
$49.46
0.3% below price
Where the price sits
18 analysts
Analyst range, low to high
$67.00$89.00
- Price $49.60
- Resistance $54.12
- Consensus $76.00
The price is just above its floor. Analysts' average target sits about 53% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about TVTXPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
Q2 2026 revenue $169.6M
- Product$161.4M95.1%
- License$8.2M4.9%
Industry
Biotechnology
Employees
497